Nevrargenics develops small molecule therapeutics that modulate Retinoid Acid Receptors (RARs) to treat neurodegenerative diseases. Their dual-acting RAR modulators promote neuroprotection and synaptic plasticity, offering disease-modifying potential for conditions like Alzheimer's and Parkinson's.
Funding
Funding not disclosed
Founders
Product
Problem
Neurodegenerative diseases are characterized by progressive neuronal loss, leading to severe motor disability, cognitive decline, and dementia. Current therapeutic approaches often fail to address the underlying disease mechanisms, resulting in limited disease-modifying potential.
Solution
Nevrargenics develops novel small molecule therapeutics that modulate Retinoid Acid Receptors (RARs) to address the unmet needs in neurodegenerative diseases. Their platform leverages a deep understanding of structure-activity relationships derived from advanced crystallography and computational modeling. The company's dual-acting RAR modulators exhibit potent genomic and non-genomic activity, promoting neuroprotection, neurite outgrowth, and synaptic plasticity. This approach targets key pathways involved in neuronal function and offers disease-modifying potential for conditions such as Alzheimer's, Parkinson's, Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia (FTD).
Target Audience
Nevrargenics targets pharmaceutical companies and biotechnology firms focused on CNS drug development, as well as academic research institutions investigating neurodegenerative disease therapeutics.
Features
- Small molecule RAR modulators with dual-acting genomic and non-genomic mechanisms.
- Sub-nanomolar potency and high selectivity for RAR modulation.
- Demonstrated neuroprotective effects, including reduction of excitotoxicity and oxidative stress.
- Promotion of neurite outgrowth, synaptic plasticity, and cell survival.
- Lead candidate, Ellorarxine™ (NVG645), shows potential for disease reversal in preclinical models of Alzheimer's, Parkinson's, and ALS.
- Exceptional drug-like properties, including good bioavailability, blood-brain barrier penetration, and CNS exposure.
- Platform technology supported by state-of-the-art capabilities in drug-receptor structural studies, binding assays, and in silico modeling.
- Pipeline targeting ALS, FTD, Parkinson's, and Alzheimer's disease.